Bolt Biotherapeutics, Inc. reported a net loss of $33.4 million for the fiscal year ending December 31, 2025, a significant improvement from the $63.1 million loss recorded in 2024. The company's total revenue remained stable at $7.7 million, primarily generated from collaboration agreements with partners such as Toray Industries and Genmab A/S. The decrease in net loss was attributed to a reduction in operating expenses, which fell from $80.7 million in 2024 to $43.8 million in 2025, largely due to cost-cutting measures and a restructuring plan that included a workforce reduction of approximately 50%.
In terms of strategic developments, Bolt Biotherapeutics has focused on its lead product candidates, BDC-4182 and BDC-3042, while pausing other pipeline programs. The company has made significant progress in its clinical trials, with BDC-4182 currently undergoing a first-in-human Phase 1 trial for gastric cancer. Additionally, the company has established a wholly-owned subsidiary in Australia to enhance its research and development capabilities in the region. The restructuring plan initiated in May 2024 and further adjustments in October 2025 were aimed at preserving cash and streamlining operations.
Operationally, Bolt Biotherapeutics has faced challenges, including a decrease in employee headcount from 50 to 23 as part of its restructuring efforts. The company has also reported a substantial accumulated deficit of $460.8 million as of December 31, 2025. Despite these challenges, the company has maintained a focus on its collaborations, which are expected to contribute to future revenue streams. The company’s cash and cash equivalents, along with marketable securities totaling $31.8 million, are projected to fund operations into early 2027, although there is substantial doubt about its ability to continue as a going concern without raising additional capital.
Looking ahead, Bolt Biotherapeutics anticipates continued investment in its research and development activities, particularly for its lead product candidates. The company is actively seeking additional funding through equity offerings, collaborations, and other means to support its ongoing clinical trials and operational needs. The success of these efforts will be critical for the company to achieve its long-term goals and potentially generate product revenue in the future.
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer treatment. Its proprietary Boltbody ISAC platform combines tumor-targeting antibodies with immune-stimulating linker-payloads to activate the innate immune system against tumors. Key programs target tumor-associated macrophages and tumor antigens like claudin 18.2 and PD-L1. The company focuses on solid tumors, leveraging collaborations and third-party manufacturing to advance its pipeline globally.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.